Inclusion criteria:

• 18 years of age or older.

• A female is eligible to enter and participate in the study if she is of:

  • Non-child-bearing potential (i.e., physiologically incapable of becoming pregnant), including any female who:
• Has had a hysterectomy, or
• Has had a bilateral oophorectomy (ovariectomy), or
• Has had a bilateral tubal ligation, or

• Is considered post-menopausal (defined as amenorrheic for at least 1 year).

  • Childbearing potential, has a negative serum pregnancy test at Screening and agrees to one of the following from 2 weeks prior to enrolment and continue through the post-study visit:
• Complete abstinence from sexual intercourse
• Oral Contraceptive, either combined or progestogen alone (must use a back up method, if have taken for less than 3 cycles)
• Injectable progestogen
• Implants of levonorgestrel
• Estrogenic vaginal ring
• Percutaneous contraceptive patches
• Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year
• Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject
• Double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent (foam/gel/film/cream/suppository)
• Eastern Cooperative Oncology Group (ECOG) Performance Status not more than 2.
• Provided written informed consent.
• Clinical lab results with ranges as stated within the protocol.

Specific to Part 1:

• Recurrent, advanced, or metastatic cancer that is known to be potentially responsive to treatment with fluoropyrimidines or oxaliplatin. Examples include gastrointestinal tumors, HER2 (ErbB2)-positive breast cancer, and lung cancers.
• Received not more than three prior chemotherapy regimens without pelvic radiotherapy or not more than two prior chemotherapy regimens if received pelvic radiotherapy.
• Platelet count of at least 75,000/mm3 (75 x 109/L).

Exclusion criteria:

• Pregnant or lactating female.
• Prior resection of the small bowel.
• Brain metastases that require additional treatment.
• Medically unfit for the study as a result of the medical interview, physical exam, or screening investigations.
• Taking any medication on the prohibited medications list as per protocol.
• History of drug or other allergy, which, in the opinion of the Investigator, contraindicates participation.
• Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drugs. These include other anilinoquinazolines, such as gefitinib [Iressa], or erlotinib [Tarceva]. The subject has received treatment with any investigational drug in the previous four weeks.
• Treatment with any biologic, cytotoxic, radiation , or hormonal (other than for contraception or replacement) therapy within four weeks. Treatment with hormones with short half-lives is allowed up to 1 week prior to study treatment after consultation with GSK medical monitor.
• Major surgery within the previous two weeks unless in the opinion of the Investigator, the subject has recovered sufficiently to begin study treatment.
• Physiological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
• Receiving concurrent coumadin therapy. Minidose coumadin for maintenance of catheters (0.5 to 1.0 mg/day), and other anticoagulation therapy are allowed on study. Subjects receiving minidose coumadin must have prothrombin time (PT) and partial thromboplastin time (PTT) within 1.2 times the ULN.
• History of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure.
• Corrected QT interval (QTc) > 450 msecs.